Literature DB >> 17275127

HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines.

Keng-Hsin Lan1, Keng-Li Lan, Wei-Ping Lee, Meei-Ling Sheu, Ming-Yuan Chen, Yung-Lu Lee, Sang-Hue Yen, Full-Young Chang, Shou-Dong Lee.   

Abstract

BACKGROUND/AIMS: HCV NS5A appears to play an important role in HCV resistance to IFN-alpha but the molecular mechanism is not fully elucidated. Most studies regarding the involvement of signal transducer and activator of transcription 1 (STAT1) in inhibition of IFN-alpha signaling by NS5A were performed in non-hepatic cell lines and their relevance may be debatable.
METHODS: We analyzed the effects of NS5A on IFN-alpha signaling through STAT1 phosphorylation in three hepatocyte-derived cell lines, Hep3B, J5 and Huh7. Interaction of NS5A and STAT1 was also investigated with co-immunoprecipitation and confocal microscopy.
RESULTS: IFN-alpha induces STAT1 activation in Hep3B cells in a dose- and time-dependent manner. Transient or stable NS5A expression inhibits STAT1 phosphorylation in a dose-dependent manner in hepatocyte-derived cell lines, whereas the levels of STAT1 phosphorylation remain unchanged in non-hepatocyte HeLa and COS7 cells despite increasing amounts of NS5A. The NS5A may interact with STAT1, specifically, the N-terminal 488 amino acids of STAT1. Furthermore, NS5A inhibits activation of interferon-stimulated gene factor 3 (ISGF3) and interferon-stimulated response element (ISRE)-driven gene expression, as demonstrated by electrophoretic mobility shift assay and luciferase assay, respectively.
CONCLUSIONS: NS5A may interact with STAT1 and inhibit IFN-alpha signaling through suppression of STAT1 phosphorylation specifically in hepatocyte-derived cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17275127     DOI: 10.1016/j.jhep.2006.11.013

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  30 in total

1.  Transcriptional repression of C4 complement by hepatitis C virus proteins.

Authors:  Arup Banerjee; Budhaditya Mazumdar; Keith Meyer; Adrian M Di Bisceglie; Ratna B Ray; Ranjit Ray
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

2.  Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cells.

Authors:  Shigeyuki Takeshita; Tatsuki Ichikawa; Naota Taura; Hisamitsu Miyaaki; Toshihisa Matsuzaki; Masashi Otani; Toru Muraoka; Motohisa Akiyama; Satoshi Miuma; Eisuke Ozawa; Masanori Ikeda; Nobuyuki Kato; Hajime Isomoto; Fuminao Takeshima; Kazuhiko Nakao
Journal:  J Gastroenterol       Date:  2011-10-25       Impact factor: 7.527

3.  Hepatitis C virus infection impairs IRF-7 translocation and Alpha interferon synthesis in immortalized human hepatocytes.

Authors:  Amit Raychoudhuri; Shubham Shrivastava; Robert Steele; Srikanta Dash; Tatsuo Kanda; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2010-09-01       Impact factor: 5.103

Review 4.  Impact of host and virus genome variability on HCV replication and response to interferon.

Authors:  Cameron J Schweitzer; T Jake Liang
Journal:  Curr Opin Virol       Date:  2013-07-06       Impact factor: 7.090

5.  TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION.

Authors:  D G Cordek; J T Bechtel; A T Maynard; W M Kazmierski; C E Cameron
Journal:  Drugs Future       Date:  2011-09       Impact factor: 0.148

6.  Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway.

Authors:  Azusa Matsumoto; Tatsuki Ichikawa; Kazuhiko Nakao; Hisamitsu Miyaaki; Kumi Hirano; Masumi Fujimito; Motohisa Akiyama; Satoshi Miuma; Eisuke Ozawa; Hidetaka Shibata; Shigeyuki Takeshita; Hironori Yamasaki; Masanori Ikeda; Nobuyuki Kato; Katsumi Eguchi
Journal:  J Gastroenterol       Date:  2009-05-13       Impact factor: 7.527

Review 7.  Innate immune responses in hepatitis C virus infection.

Authors:  Kui Li; Stanley M Lemon
Journal:  Semin Immunopathol       Date:  2012-08-07       Impact factor: 9.623

8.  Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.

Authors:  Celia Perales; Nathan M Beach; Isabel Gallego; Maria Eugenia Soria; Josep Quer; Juan Ignacio Esteban; Charles Rice; Esteban Domingo; Julie Sheldon
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

Review 9.  Future classes of hepatitis C virus therapeutic agents.

Authors:  Jennifer Y Chen; Raymond T Chung
Journal:  Infect Dis Clin North Am       Date:  2012-12       Impact factor: 5.982

10.  Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells.

Authors:  Anja Duechting; Carsten Tschöpe; Heike Kaiser; Tobias Lamkemeyer; Nobuyuki Tanaka; Susanne Aberle; Florian Lang; Joseph Torresi; Reinhard Kandolf; C-Thomas Bock
Journal:  J Virol       Date:  2008-06-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.